On October 13, Ascletis Pharma (01672) announced that its GLP-1R/GIPR dual-target agonist peptide, ASC35, has entered clinical development. In a head-to-head non-human primate study, the drug demonstrated a mean apparent half-life of approximately 14 days, six times longer than tilpotide, supporting once-monthly subcutaneous administration.

ASC35's drug exposure after intravenous and subcutaneous injection is approximately 80% and 70% higher than that of tilpotide, respectively. Furthermore, ASC35's agonist activity at GLP-1 and GIP receptors is approximately four times stronger than that of tilpotide. In a study of diet-induced obese mice, ASC35 achieved a 33.6% weight loss effect, compared to 19.6% for tilpotide, representing a relative improvement of approximately 71% in weight loss.

The company expects to submit a new drug clinical trial application for ASC35 to the U.S. Food and Drug Administration in the second quarter of 2026. The announcement mentioned that ASC35 was independently developed based on the company's AI-assisted drug discovery and ultra-long-acting drug development platform technologies, and has shown its potential in treating obesity and other metabolic diseases.

https://finance.eastmoney.com/a/202510133531871037.html